Gu W, Zhang H, Lu Y, Li M, Yang S, Liang J
Cancer Res Treat. 2023; 55(3):841-850.
PMID: 36791768
PMC: 10372607.
DOI: 10.4143/crt.2022.1438.
Obaya A, Mohammed A, Rashied H, Morsy A, Osman G, Allam A
Asian Pac J Cancer Prev. 2021; 22(4):1025-1034.
PMID: 33906293
PMC: 8325139.
DOI: 10.31557/APJCP.2021.22.4.1025.
Lai E, Liscia N, Donisi C, Mariani S, Tolu S, Pretta A
Cancers (Basel). 2020; 12(5).
PMID: 32413973
PMC: 7281737.
DOI: 10.3390/cancers12051214.
Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L
J Clin Oncol. 2019; 37(33):3099-3110.
PMID: 31539295
PMC: 6864846.
DOI: 10.1200/JCO.19.01254.
Ma C, Huang C, Chang T, Tsai H, Su W, Yeh Y
Transl Oncol. 2018; 12(3):502-512.
PMID: 30594039
PMC: 6307535.
DOI: 10.1016/j.tranon.2018.12.003.
Biomarker threshold adaptive designs for survival endpoints.
Diao G, Dong J, Zeng D, Ke C, Rong A, Ibrahim J
J Biopharm Stat. 2018; 28(6):1038-1054.
PMID: 29436940
PMC: 6342463.
DOI: 10.1080/10543406.2018.1434191.
Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers.
Salem M, Weinberg B, Xiu J, El-Deiry W, Hwang J, Gatalica Z
Oncotarget. 2017; 8(49):86356-86368.
PMID: 29156800
PMC: 5689690.
DOI: 10.18632/oncotarget.21169.
EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis.
Yuan J, Zhang Y, Li H, Mao C
Medicine (Baltimore). 2017; 96(7):e6151.
PMID: 28207548
PMC: 5319537.
DOI: 10.1097/MD.0000000000006151.
Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond.
Delaney C, Frank S, Huang R
Chin J Cancer. 2015; 34(4):149-60.
PMID: 25962919
PMC: 4593375.
DOI: 10.1186/s40880-015-0007-9.
Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status.
Peeters M, Karthaus M, Rivera F, Terwey J, Douillard J
Drugs. 2015; 75(7):731-48.
PMID: 25895463
PMC: 4419154.
DOI: 10.1007/s40265-015-0386-x.
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.
Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt N, Mitchell E
Clin Cancer Res. 2014; 20(16):4240-50.
PMID: 24919569
PMC: 4371780.
DOI: 10.1158/1078-0432.CCR-13-2752.
Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.
Aprile G, Lutrino S, Ferrari L, Casagrande M, Bonotto M, Ongaro E
World J Gastroenterol. 2014; 19(46):8474-88.
PMID: 24379565
PMC: 3870493.
DOI: 10.3748/wjg.v19.i46.8474.
Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab.
Price T, Hardingham J, Lee C, Townsend A, Wrin J, Wilson K
Cancer Med. 2013; 2(3):277-85.
PMID: 23930204
PMC: 3699839.
DOI: 10.1002/cam4.75.
Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review.
Merla A, Goel S
Chemother Res Pract. 2012; 2012:387172.
PMID: 23097702
PMC: 3477664.
DOI: 10.1155/2012/387172.
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A
Clin Colorectal Cancer. 2012; 11(2):143-50.
PMID: 22285706
PMC: 3350566.
DOI: 10.1016/j.clcc.2011.12.001.
